Publicacións en colaboración con investigadores/as de Universidad de Sevilla (1)

2023

  1. Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain

    Cost Effectiveness and Resource Allocation, Vol. 21, Núm. 1